Tags

Type your tag names separated by a space and hit enter

High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Vox Sang. 1998; 74(4):225-7.VS

Abstract

BACKGROUND AND OBJECTIVES

Human parvovirus B19 is a potential risk to hemophiliac patients receiving blood products.

MATERIALS AND METHODS

To determine the prevalence of the corresponding antibody in patients with hemophilia A or B von Willebrand's disease, we tested 326 hemophilia patients for anti-B19 IgG. The results were compared with those of 203 age-matched controls (male blood donors and children).

RESULTS

The overall prevalence of B19 IgG in the hemophilia patients was 302/326, and in the controls 123/203. Below the age of 10, hemophilia patients had a higher prevalence of B19 IgG (76%, 42/55) than the controls (23%, 11/48; p < 0.00001). In those below the age of 5 who had been treated exclusively with monoclonally purified concentrate, it made no difference whether the product was pasteurized or solvent-detergent treated. There was significantly lower incidence in patients who were rarely treated.

CONCLUSION

Parvovirus B19 if frequently transmitted in blood products. Existing virus-inactivating methods do not prevent transmission.

Authors+Show Affiliations

Van Creveld Clinic, University Hospital Utrecht, The Netherlands. E.MauserBunschoten@digd.AZU.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

9691402

Citation

Mauser-Bunschoten, E P., et al. "High Prevalence of Parvovirus B19 IgG Antibodies Among Dutch Hemophilia Patients." Vox Sanguinis, vol. 74, no. 4, 1998, pp. 225-7.
Mauser-Bunschoten EP, Zaaijer HL, van Drimmelen AA, et al. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Vox Sang. 1998;74(4):225-7.
Mauser-Bunschoten, E. P., Zaaijer, H. L., van Drimmelen, A. A., de Vries, S., Roosendaal, G., van den Berg, H. M., & Lelie, P. N. (1998). High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Vox Sanguinis, 74(4), 225-7.
Mauser-Bunschoten EP, et al. High Prevalence of Parvovirus B19 IgG Antibodies Among Dutch Hemophilia Patients. Vox Sang. 1998;74(4):225-7. PubMed PMID: 9691402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. AU - Mauser-Bunschoten,E P, AU - Zaaijer,H L, AU - van Drimmelen,A A, AU - de Vries,S, AU - Roosendaal,G, AU - van den Berg,H M, AU - Lelie,P N, PY - 1998/8/6/pubmed PY - 2000/10/6/medline PY - 1998/8/6/entrez SP - 225 EP - 7 JF - Vox sanguinis JO - Vox Sang VL - 74 IS - 4 N2 - BACKGROUND AND OBJECTIVES: Human parvovirus B19 is a potential risk to hemophiliac patients receiving blood products. MATERIALS AND METHODS: To determine the prevalence of the corresponding antibody in patients with hemophilia A or B von Willebrand's disease, we tested 326 hemophilia patients for anti-B19 IgG. The results were compared with those of 203 age-matched controls (male blood donors and children). RESULTS: The overall prevalence of B19 IgG in the hemophilia patients was 302/326, and in the controls 123/203. Below the age of 10, hemophilia patients had a higher prevalence of B19 IgG (76%, 42/55) than the controls (23%, 11/48; p < 0.00001). In those below the age of 5 who had been treated exclusively with monoclonally purified concentrate, it made no difference whether the product was pasteurized or solvent-detergent treated. There was significantly lower incidence in patients who were rarely treated. CONCLUSION: Parvovirus B19 if frequently transmitted in blood products. Existing virus-inactivating methods do not prevent transmission. SN - 0042-9007 UR - https://www.unboundmedicine.com/medline/citation/9691402/High_prevalence_of_parvovirus_B19_IgG_antibodies_among_Dutch_hemophilia_patients_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0042-9007&amp;date=1998&amp;volume=74&amp;issue=4&amp;spage=225 DB - PRIME DP - Unbound Medicine ER -